{"brief_title": "An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)", "brief_summary": "This protocol will study an investigational drug treatment plan against standard therapy in the prevention of chemotherapy-induced nausea and vomiting in patients diagnosed with breast cancer who are to be treated with up to 4 cycles of non-cisplatin moderately emetogenic chemotherapy.", "condition": ["Nausea", "Vomiting", "Breast Neoplasms"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["MK0869, aprepitant / Duration of Treatment: 3 days", "Comparator: ondansetron / Duration of Treatment: 3 days"], "criteria": "Inclusion Criteria: - Patient with a diagnosis of breast cancer requiring treatment with non-cisplatin moderately emetogenic chemotherapy. Exclusion Criteria: - Patient has a central nervous system malignancy. - Patient will receive radiation to the abdomen or pelvis.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Chemotherapy-Induced Nausea and Vomiting", "mesh_term": ["Nausea", "Vomiting", "Breast Neoplasms", "Aprepitant", "Fosaprepitant", "Ondansetron"], "id": "NCT00092183"}